Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis-Reference-Cited by-同舟云学术

Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis

Published:2021-01-02 Issue:4 Volume:113 Page:500-507
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Morishita Soji^ORCID,Ochiai Tomonori,Misawa Kyohei,Osaga Satoshi,Inano Tadaaki,Fukuda Yasutaka,Edahiro Yoko,Ohsaka Akimichi,Araki Marito,Komatsu Norio^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-020-03054-x.pdf

Reference33 articles.

1. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.

2. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.

3. Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310.

4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.

5. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–31.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing;Frontiers in Genetics;2023-09-08

2. Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms;International Journal of Molecular Sciences;2023-08-21

3. Analysis of somatic mutations in the JAK2, CALR, MPL and ASXL1 genes and evaluation of their impact on the survival of patients with myelofibrosis;Oncohematology;2023-03-15

4. Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia;European Journal of Haematology;2022-10-17

5. Advances in the Study of High-Risk Gene Mutations for Primary Myelofibrosis;Journal of Biosciences and Medicines;2022